drugset / Trial / NCT02690857

Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)

NCT02690857

Phase 2 Completed 10 enrolled Hospices Civils de Lyon
RandomizedCrossoverQuadruple-blindTreatment

Summary

Patients with Cystic Fibrosis have increased oxidative stress and impaired antioxidant systems. Under certain conditions, docosahexaenoic acid (DHA) intake may have a favorable role in reducing redox status. In this randomized, double-blind, cross-over study, DHA (Pro-Mind) and placebo (sunflower oil) capsules, will be given, daily to 10 patients, 5 mg/kg for 2 weeks then 10 mg/kg for the next 2 weeks. Biomarkers of lipid peroxidation and vitamin E levels will be measured. Plasma and platelet lipid compositions will be determined.

Timeline

Start
2010-05
Primary completion
2010-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified 10 mg/kg Oral

Indications